Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Epic Sciences (San Diego, CA), a preclinical-stage biotechnology company focused on cancer diagnostics, closed a $13M Series B financing. Participants include Domain Associates, Roche Venture Fund, and Pfizer Venture Investments. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective [...]

Metamark Genetics (Cambridge, MA), a preclinical-stage molecular diagnostics company focused on cancer, closed a $13M Series B financing. Participants were not identified. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account Access HERE

Advanced Cell Diagnostics (Hayward, CA), a clinical-stage biotechnology company focused on diagnostics and development of therapeutics for Age-related Macular Degeneration and Stargardt’s Macular Dystrophy, closed a $12M Series B financing. Participants include New Leaf Venture Partners and Morningside Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access [...]

GeneWeave Biosciences (San Jose, CA) a development-stage molecular diagnostic company focused on using bacterial DNA for the detection of pathogens, closed a $12M Series A financing. Participants include Decheng Capital, Claremont Creek Ventures and X/Seed Capital. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Nuclea Biotechnologies (Pittsfield, MA) a commercial-stage diagnostic company focused on in vitro companion diagnostic assays based on gene and protein expression profiles and biomarkers associated with an individual’s tumor or specific disease state, closed a $3.4M Series B financing bringing the total round to $9.8M. Participants were not identified. Note: Closing out 1Q deals. Thanx [...]

Strand Diagnostics (Indianapolis, IN) a commercial-stage molecular diagnostics company focused on DNA screening of breast and prostate biopsy samples and patient DNA for molecular cancer diagnosis verification, closed a $30M Series A financing. Participants include NantWorks. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

Natura, f/k/a Gene Security Network (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and diseases such as Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

Natura (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

Aria Diagnostics (San Jose, CA) a clinical-stage molecular diagnostics focused on cell-free DNA (cfDNA) blood analysis of pregnant womem to detect fetal trisomises, closed a $52.7M million in Series C financing. Participants include Meritech Capital Partners, Venrock and Domain Associates.

Roka BioScience (Warren, NJ) a development-stage diagnostic company focused on molecular assays for monitoring food safety applications and biopharmaceutical manufacturing, closed a $27.5M Series D financing. Participants include Aisling Capital, OrbiMed, New Enterprise Associates and TPG Biotech.

Firefly BioWorks (Cambridge, MA) a development-stage biotechnologycompany focused on an open platform multiplexed biological assay standardization for the quantification of biological function, closed a $2M Series A financing. Participants were not identified.

Foundation Medicine (Cambridge, MA) a development-stage diagnostic company focused on cancer genome analysis, closed a $16M Series A financing, bringing the total round to $33.5M. Participants include Kleiner Perkins Caufield & Byers, Google Ventures and Third Rock Ventures.

« Previous Entries  Next Page »

to top of page...